|Project Title||Principal Investigator||Institution|
|Neuropharmacology of motivation and reinforcement in mouse models of autistic spectrum disorders||Malanga, C.J.||University of North Carolina School of Medicine|
|Evaluation of altered fatty acid metabolism via gas chromatography/mass spectroscopy and time-of-flight secondary ion mass spectroscopy imaging in the propionic acid rat model of autism spectrum disorders||MacFabe, Derrick||University of Western Ontario|
|Autism iPSCs for studying function and dysfunction in human neural development||Loring, Jeanne||The Scripps Research Institute|
|Insight into MeCP2 function raises therapeutic possibilities for Rett syndrome||Lomvardas, Stavros||University of California, San Francisco|
|Using Drosophila to model the synaptic function of the autism-linked NHE9||Littleton, J. Troy||Massachusetts Institute of Technology|
|Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders - 1||Lipton, Stuart||Burnham Institute|
|Serotonin, corpus callosum, and autism||Lin, Rick||University of Mississippi Medical Center|
|The genetics of restricted, repetitive behavior: An inbred mouse model||Lewis, Mark||University of Florida|
|Behavioral and physiological consequences of disrupted Met signaling||Levitt, Pat||University of Southern California|
|Shank3 mutant characterization in vivo||Kouser, Mehreen||University of Texas Southwestern Medical Center|
|Animal model of speech sound processing in autism||Kilgard, Michael||University of Texas at Dallas|
|Control of synaptic protein synthesis in the pathogenesis and therapy of autism||Kelleher, Raymond||Massachusetts General Hospital|
|Investigating the effects of chromosome 22q11.2 deletions||Karayiorgou, Maria||Columbia University|
|Functional study of synaptic scaffold protein SHANK3 and autism mouse model||Jiang, Yong-Hui||Duke University|
|Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes||Jarstfer, Michael||University of North Carolina at Chapel Hill|
|Neurogenomics in a model for procedural learning||Hilliard, Austin||University of California, Los Angeles|
|High content screens of neuronal development for autism research||Halpain, Shelley||University of California, San Diego|
|Exploring the neuronal phenotype of autism spectrum disorders using induced pluripotent stem cells||Hallmayer, Joachim; Dolmetsch, Ricardo||Stanford University|
|Genomic imbalances at the 22q11 locus and predisposition to autism||Gogos, Joseph||Columbia University|
|Identification of autism genes that regulate synaptic Nrx/Nlg signaling complexes||Garner, Craig||Stanford University|
|Deriving neuroprogenitor cells from peripheral blood of individuals with autism||Fujinami, Robert||University of Utah|
|Functional genomic dissection of language-related disorders||Fisher, Simon||University of Oxford|
|Dissecting the circuitry basis of autistic-like behaviors in mice||Feng, Guoping||Massachusetts Institute of Technology|
|Synaptic and circuitry mechanisms of repetitive behaviors in autism||Feng, Guoping||Massachusetts Institute of Technology|
|Patient iPS cells with copy number variations to model neuropsychiatric disorders||Ellis, James||The Hospital for Sick Children|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.
IACC Recommended Budget: $75,000,000 over 5 years
|4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 90 projects were supported to develop animal models.
Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.